AstraZeneca vs L'Oreal: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and L'Oreal side by side

1. 1909L'Oreal

   Company Founded

   Eugène Schueller registers the Société Française de Teintures Inoffensives pour Cheveux in Paris with 800 francs in capital, beginning commercial sale of his Oréale hair dye formula to Parisian hairdressers.

2. 1912L'Oreal

   First International Expansion

   L'Oréal hair dyes reach distribution in the Netherlands, Austria, and Italy, establishing the international distribution ambition that would eventually span 150 countries.

3. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

4. 1929L'Oreal

   Imédia First Consumer Hair Dye

   L'Oréal introduces Imédia, the world's first hair dye product formulated for home application by consumers, marking the company's pivot from purely professional B2B to consumer-facing distribution.

5. 1963L'Oreal

   Euronext Paris IPO

   L'Oréal lists on the Paris Stock Exchange, providing capital for accelerated international expansion and establishing the public shareholder structure that persists today alongside the Bettencourt family's controlling stake.

6. 1971L'Oreal

   'Because You're Worth It' Campaign Launched

   Copywriter Ilon Specht creates the 'Because You're Worth It' tagline for L'Oréal Paris one of the most enduring advertising phrases in consumer goods history, reframing beauty products as expressions of female self-worth rather than instruments of male approva…

7. 1991L'Oreal

   Acquisition of La Roche-Posay

   L'Oréal acquires La Roche-Posay, the French dermo-cosmetic brand founded in 1975, establishing its first significant presence in the pharmacy channel and laying groundwork for what would become the Dermatological Beauty division.

8. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

9. 1996L'Oreal

   Maybelline Acquisition

   L'Oréal acquires Maybelline New York from Wasserstein Perella for approximately $758 million, instantly becoming the global leader in mass-market color cosmetics and significantly expanding its North American market position.

10. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

11. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

12. 2000L'Oreal

    Matrix and Kiehl's Acquisitions

    L'Oréal acquires professional hair care brand Matrix and American apothecary brand Kiehl's Since 1851, broadening both the professional channel and the prestige specialty retail presence in the U.S. Market.

13. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

14. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

19. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

20. 2017L'Oreal

    CeraVe Acquisition $1.3 Billion

    L'Oréal acquires CeraVe, AcneFree, and Ambi from Valeant Pharmaceuticals for $1.3 billion.

21. 2018L'Oreal

    ModiFace Acquisition Beauty Tech

    L'Oréal acquires ModiFace, a Toronto-based augmented reality and artificial intelligence beauty technology company, establishing a proprietary virtual try-on and skin diagnostic platform deployed across brand apps, retail partner websites, and social media pla…

22. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

23. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

24. 2021L'Oreal

    Nicolas Hieronimus Becomes CEO

    Nicolas Hieronimus, a 30-year L'Oréal veteran who led the Luxe division's transformation, succeeds Jean-Paul Agon as Chief Executive Officer, bringing strategic continuity while accelerating digital commerce and sustainability investment.

25. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

26. 2023L'Oreal

    Aesop Acquisition $2.5 Billion

    L'Oréal completes the acquisition of Aesop, the Australian premium natural beauty brand, from Natura &Co for $2.525 billion the company's largest acquisition in over a decade and a strategic entry into the premium wellness and natural beauty segment.

27. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

28. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

29. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

30. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

31. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

32. 2025L'Oreal

    FY2025 Sales Reach 44.052 Billion

    LOral reported 44.052 billion in FY2025 sales, 4.0% like-for-like growth, 8.892 billion in operating profit, 6.127 billion in net profit after non-controlling interests, and more than 95,000 employees.

33. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

34. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

35. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

36. 2026L'Oreal

    Kering Beauté Acquisition Completed

    L'Oréal closed the ~$4.52 billion (€4 billion) purchase of Kering Beauté, including Creed, with 50-year licences for Bottega Veneta, Balenciaga and, from July 2027, Gucci.

37. 2026L'Oreal

    Record First-Half Margin

    H1 2026 sales reached ~$26.9 billion (€23.77 billion), up 6.8% like-for-like, with a record 21.3% operating margin.

Acquisitions

Questions about AstraZeneca vs L'Oreal